In 2014 BIOCAD entered into a long-term agreement with BAXTER in order to provide hemophilia A patients in Russia and CIS countries with recombinant antihemophilic factor ADVATE

BIOCAD as knowledge-based company is focused on the technology know-how and research and development capabilities.
With the biosimilars and innovative products in portfolio BIOCAD is turned to fast growing foreign economies as well as to well established markets.

BIOCAD is open to cooperation with significant synergy potential and a view to robust expansion of international markets based on mutual benefits. Understanding the complexity of the challenges we face, we stay within our core competencies, and we use all opportunities from our related knowledge. We do this by strengthening our own research and development activities, and by actively working with our colleagues – scientists, doctors, and pharmacists.

BIOCAD is interested in cooperation in the following areas: